Skip to main content
XERSXeris Biopharma Holdings, Inc.Sell5.9·$16.97
SellHigh Confidence
Investment thesis

Xeris Biopharma combines 38% revenue growth and a Rule-of-40 pass with an overbought, late-cycle momentum setup (RSI 89) and value-trap warning signs — 19.9x leverage and modest insider selling — that the engine flags as risk.

Thesis pillars

  • Strong Growth Positive Momentum→Stable
  • Elevated Leverage Value Trap Risk↓Deteriorating
  • Overbought Late Cycle Distribution Risk↓Deteriorating
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Jul 5, 2026, based on the 10-K filed Mar 2, 2026· older than 90 days

Full reasoning →

Open full analysis

Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis

SellVALUE-TRAP 2/5GrowthHigh Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Sell if holding. At $16.97, A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: Regis Technologies; Concentration risk — Supplier: Lonza Tampa.

Xeris Biopharma is a commercial-stage biopharmaceutical company selling three FDA-approved therapies for chronic endocrine and neurological diseases in the United States: Recorlev for Cushing's syndrome, Gvoke ready-to-use glucagon for severe hypoglycemia, and Keveyis for... Read more

QualityF-score8 / 9FCF yield1.65%
Stop $15.78Analyst target $15.04(reached)A.R:R -0.8:1
Analyst consensus$17.29+1.9%7 analysts with price targets
$16.97price
$17.29mean
$12
$21

Sell if holding. At $16.97, A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: Regis Technologies; Concentration risk — Supplier: Lonza Tampa. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.9/10, high confidence.

Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 101d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.

10-K grounded · weekly refresh

About Xeris Biopharma Holdings, Inc.

About Xeris Biopharma Holdings, Inc.

Xeris Biopharma markets three FDA-approved products in the United States: Recorlev for Cushing's syndrome, Gvoke for severe hypoglycemia, and Keveyis for primary periodic paralysis, alongside a Phase 3-ready pipeline candidate, XP-8121, for hypothyroidism. The company turned profitable in 2025 with net income of $0.6 million, following net losses of $54.8 million in 2024 and $62.3 million in 2023, while carrying $200.0 million in term loans and $33.6 million in convertible notes.

Xeris generates revenue through U.S. prescription sales of Recorlev, Gvoke, and Keveyis, distributed via specialty pharmacies and wholesale customers under commercial agreements with a limited number of logistics vendors. The company outsources all manufacturing to third-party CMOs rather than operating its own facilities: Regis Technologies is the company's sole source for levoketoconazole, the active ingredient in Recorlev, and Lonza Tampa is its sole source for Recorlev's finished drug product, while Bachem Americas serves as primary source for Gvoke's glucagon API and Pyramid Laboratories as primary source for Gvoke's finished drug product. Taro Pharmaceuticals manufactures Keveyis under a supply agreement that lets Xeris manufacture the product itself or through another third party if Taro doesn't renew. Xeris also pursues formulation partnerships that license its XeriSol and XeriJect non-aqueous injectable technologies to other pharmaceutical companies' proprietary drugs and biologics, a secondary, royalty-oriented revenue stream distinct from its own product sales.

Show full overview

Keveyis illustrates the patent-cliff risk facing Xeris's older assets: the product lost orphan drug exclusivity in August 2022, and the FDA approved generic dichlorphenamide versions in 2022 and again in November 2025, most recently to Rising Pharmaceuticals, while Xeris's own attempt to restore exclusive rights through two pending patent applications remains on appeal at the Federal Circuit. Recorlev, by contrast, retains patent protection through 2040 and orphan exclusivity through December 30, 2028, positioning it as the more durable of the company's three approved products even as Keveyis faces mounting generic competition.

See also: Healthcare · Drug Manufacturers - Specialty & Generic

From Xeris Biopharma Holdings, Inc.'s most recent 10-K filing, extracted July 6, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

No fresh coverage since Oct 29, 2026

Recent Developments — Xeris Biopharma Holdings, Inc.

Latest item Oct 29, 2026 · Generated 2026-11-22T11:42:10Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Mar 4, 2027101d to earnings· next earnings call

Thesis

Rewards
Sector modifier (Healthcare): +0.8
Strong growth profile
Risks
Concentration risk — Supplier: Regis Technologies
Concentration risk — Supplier: Lonza Tampa
Analyst target reached - limited upside remaining

Key Metrics

P/E (TTM)—
P/E (Fwd)63.6
Mkt Cap$3.1B
EV/EBITDA54.2
Profit Mgn-1.8%
ROE-27.1%
Rev Growth44.2%
Beta0.84
DividendNone
Analysts with ratings13

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C1.83bearish
IV90%elevated

Concentration Risks(10-K Item 1A)

  • HIGHSupplierRegis Technologies
    10-K Item 1: 'Regis Technologies, Inc. ... its facility in Illinois is our sole source for API.'
  • HIGHSupplierLonza Tampa
    10-K Item 1: 'Lonza Tampa, LLC ... its facility in Florida is our sole source for drug product.'
  • MEDIUMSupplierBachem
    10-K Item 1: 'Bachem Americas, Inc., ... is our primary commercial source for glucagon API.'
  • MEDIUMSupplierPyramid Laboratories
    10-K Item 1: 'Pyramid Laboratories, Inc. ... Its facility in California is our primary source for drug product.'

Material Events(8-K, last 90d)

  • 2026-06-30Item 5.02LOW
    Board expanded from 7 to 8 members and appointed Nerissa Kreher, M.D. as a Class III director effective July 1, 2026. Routine board expansion, no departure involved.
    SEC filing →
  • 2026-04-21Item 5.02LOW
    Director Jeffrey Sherman notified the company on April 20, 2026 he will retire from the Board and not stand for reelection at the 2026 Annual Meeting; board size to shrink from 8 to 7. Explicitly not due to any disagreement with the company.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker·1 ceiling hit

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank
0.8
Quality Rank
2.7
Growth Rank
8.3
Industry growth leader
GatesA.R:R -0.8=NEGATIVEExecutive change: officer departure/appointmentMomentum 6.9>=5.5Insider activity: OKNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 101d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
95 · Overbought
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $10.08Resistance $17.28

Price Targets

A.Upside-11.4%
A.R:R-0.8:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeCrisis

Risk Alerts

! Target reached (-11.4% upside)
! Negative risk/reward — downside exceeds upside

Earnings

B
M
M
M
1/4 beats
Next Earnings2027-03-04 (101d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is XERS stock a buy right now?

Sell if holding. At $16.97, A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: Regis Technologies; Concentration risk — Supplier: Lonza Tampa. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $15.78. Score 5.9/10, high confidence.

What is the XERS stock price target?

Analyst target $15.04 reached (−11.4% from $16.97); no take-profit level is published. Prior stop was $15.78. Stop-loss: $15.78.

What are the risks of investing in XERS?

Concentration risk — Supplier: Regis Technologies; Concentration risk — Supplier: Lonza Tampa; Analyst target reached - limited upside remaining.

Is XERS overvalued or undervalued?

Xeris Biopharma Holdings, Inc. trades at a P/E of N/A (forward 63.6). TrendMatrix value score: 4.7/10. Verdict: Sell.

What do analysts say about XERS?

13 analysts rate XERS, with a consensus score of 4.2/5. 7 analysts publish price targets averaging $17.

What does Xeris Biopharma Holdings, Inc. do?Xeris Biopharma is a commercial-stage biopharmaceutical company selling three FDA-approved therapies for chronic...

Xeris Biopharma is a commercial-stage biopharmaceutical company selling three FDA-approved therapies for chronic endocrine and neurological diseases in the United States: Recorlev for Cushing's syndrome, Gvoke ready-to-use glucagon for severe hypoglycemia, and Keveyis for periodic paralysis. The company reported net income of $0.6 million in 2025, a turnaround from net losses of $54.8 million and $62.3 million in 2024 and 2023, and relies on third-party contract manufacturers, including sole-source suppliers for two of Recorlev's key inputs.

Related stocks: SUPN (Supernus, Inc.) · INDV (Indivior Pharmaceuticals, Inc.) · ANIP (ANI Pharmaceuticals, Inc.) · ETON (Eton Pharmaceuticals, Inc.) · BCRX (BioCryst Pharmaceuticals, Inc.)
Home › Stocks › XERS

Latest news

Latest News

TradingKey116d agoEarnings
Business Wire88d agoProduct
MarketBeat95d ago
Sahm95d ago
GuruFocus109d ago
GuruFocus54d agoMerger Acquisition
Yahoo Finance54d agoMerger Acquisition
Marketscreener.com54d agoMerger Acquisition
Marketscreener.com54d agoMerger Acquisition
Yahoo Finance54d agoMerger Acquisition
Investing.com54d ago
Investing.com Nigeria54d ago
TradingKey117d ago
Tradingkey.com117d ago
24/7 Wall St.61d ago
Sahm96d ago
Investing.com India40d ago
Investing.com India40d ago
Investing.com India40d ago
GuruFocus47d agoAnalyst
Loading more...